Related Experiment Video

Updated: Jan 31, 2026

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

9.1K

Can beta blockers be safely used in patients with recent myocardial infarction who also have congestive heart

D G Julian

    Circulation
    |June 1, 1983
    PubMed

    Insights

    Beta-adrenoceptor drugs are likely safe for acute myocardial infarction patients without hypotension or heart failure. Use with caution and hemodynamic monitoring if cardiac output is low or end-diastolic pressure is raised.

    Area of Science:

    • Cardiology
    • Pharmacology

    Background:

    • Uncertainty surrounds the use of beta-adrenoceptor drugs in acute myocardial infarction (AMI).
    • Previous concerns regarding adverse effects have diminished.

    Purpose of the Study:

    • To clarify the indications and contraindications for beta-adrenoceptor drug therapy in AMI.
    • To assess the safety profile of these agents in AMI patients.

    Main Methods:

    • Review of existing literature and clinical evidence regarding beta-adrenoceptor blockade in AMI.
    • Analysis of patient subgroups based on hemodynamic parameters.

    Main Results:

    • Beta-adrenoceptor drugs can likely be safely administered to AMI patients without hypotension or overt cardiac failure.
    • Caution and close hemodynamic monitoring are advised for patients with suspected elevated end-diastolic pressure or low cardiac output.

    Conclusions:

    • Beta-adrenoceptor therapy is generally safe in AMI, except in specific high-risk hemodynamic situations.
    • Careful patient selection and monitoring are crucial for optimizing outcomes in AMI treatment with beta-adrenoceptor drugs.

    More Related Videos

    Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment08:24

    Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment

    Published on: May 25, 2020

    7.4K
    Acute Myocardial Infarction in Rats07:45

    Acute Myocardial Infarction in Rats

    Published on: February 16, 2011

    54.6K

    Related Concept Videos

    Heart Failure VI: Adjunct Therapies01:22

    Heart Failure VI: Adjunct Therapies

    Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
    332
    Heart Failure II: Pathophysiology01:29

    Heart Failure II: Pathophysiology

    Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
    907
    Heart Failure I: Introduction01:27

    Heart Failure I: Introduction

    Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
    877
    Heart Failure Drugs: β-Blockers01:22

    Heart Failure Drugs: β-Blockers

    β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
    918
    Pathophysiology of Heart Failure01:17

    Pathophysiology of Heart Failure

    Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
    3.6K
    Heart Failure Drugs: Diuretics01:22

    Heart Failure Drugs: Diuretics

    Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
    963